Genomic analysis of intracranial and subcortical brain volumes yields polygenic scores accounting for variation across ancestries - García-Marín, Luis M; Campos, Adrian I; Diaz-Torres, Santiago; Rabinowitz, Jill A; Ceja, Zuriel; Mitchell, Brittany L; Grasby, Katrina L; Thorp, Jackson G; Agartz, Ingrid; Alhusaini, Saud; Ames, David; Amouyel, Philippe; et al. (medRxiv, 2024)
Subcortical brain structures are involved in developmental, psychiatric and neurological disorders. We performed GWAS meta-analyses of intracranial and nine subcortical brain volumes (brainstem, caudate nucleus, putamen, hippocampus, globus pallidus, thalamus, nucleus accumbens, amygdala and, for the first time, the ventral diencephalon) in 74,898 participants of European ancestry. We identified 254 independent loci associated with these brain volumes, explaining up to 35% of phenotypic variance. We observed gene expression in specific neural cell types across differentiation time points, including genes involved in intracellular signalling and brain ageing-related processes. Polygenic scores for brain volumes showed predictive ability when applied to individuals of diverse ancestries. We observed causal genetic effects of brain volumes with Parkinson’s disease and ADHD. Findings implicate specific gene expression patterns in brain development and genetic variants in comorbid neuropsychiatric disorders, which could point to a brain substrate and region of action for risk genes implicated in brain diseases.Competing Interest StatementIA received speaker honorarium Lundbeck; OAA is a consultant to Cortechs.ai and Precision Health, speakers honorarium from Lundbeck, Janssen, Otsuka, Sunovion; HB is an Advisory Board Member or Consultant to Biogen, Eisai, Eli Lilly, Roche, Skin2Neuron, Cranbrook Care and Montefiore Homes; CRKC has received past partial research support from Biogen, Inc. (Boston, USA) for work unrelated to the topic of this manuscript; AMD is the Principal Investigator of a research agreement between General Electric Healthcare and the University of California, San Diego (UCSD); he is a Founder of and hold equity in CorTechs Labs, Inc. I am a member of the Scientific Advisory Board of Human Longevity, Inc., and the Mohn Medical Imaging and Visualization Center in Bergen, Norway. The terms of these arrangements have been reviewed and approved by UCSD in accordance with its conflict-of-interest policies; BF has received educational speaking fees from Medice; HJG has received travel grants and speakers honoraria from Fresenius Medical Care, Neuraxpharm, Servier and Janssen Cilag as well as research funding from Fresenius Medical Care; DPH is a full time employee of Genentech, Inc; NH is a shareholder various manufacturers of medical technology; AM-L has received consultant fees from Daimler und Benz Stiftung, EPFL Brain Mind Institute, Fondation FondaMental, Hector Stiftung II, Invisio, Janssen-Cilag GmbH, Lundbeck A/S, Lundbeckfonden, Lundbeck Int. Neuroscience Foundation, Neurotorium, MedinCell, The LOOP Zurich, University Medical Center Utrecht, University of Washington, Verein fur Mentales Wohlbefinden, von Behring-Rontgen-Stiftung; speaker fees from Arztekammer Nordrhein, Caritas, Clarivate, Dt. Gesellschaft fur Neurowissenschaftliche Begutachtung, Gentner Verlag, Landesarztekammer Baden-Wurttemberg, LWL Bochum, Northwell Health, Ruhr University Bochum, Penn State University, Society of Biological Psychiatry, University Prague, Vitos Klinik Rheingau and editorial and/or author fees from American Association for the Advancement of Science, ECNP, Servier Int., Thieme Verlag; WN is founder of Quantib BV and was scientific lead of Quantib BV until Jan 31, 2023; MMN has received fees for membership in an advisory board from HMG Systems Engineering GmbH (Furth, Germany), for membership in the Medical-Scientific Editorial Office of the Deutsches Arzteblatt, and for serving as a consultant for EVERIS Belgique SPRL in a project of the European Commission (REFORM/SC2020/029). MMN receives salary payments from Life & Brain GmbH and holds shares in Life & Brain GmbH. All these concerned activities outside the submitted work; BMP serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson; AJS receives support from multiple NIH grants (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U19 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, U01 AG068057, U01 AG072177, and U19 AG074879). He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor); Bayer Oncology (Scientific Advisory Board); Eisai (Scientific Advisory Board); Siemens Medical Solutions USA, Inc. (Dementia Advisory Board); NIH NHLBI (MESA Observational Study Monitoring Board); Springer-Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging and Behavior); MS received funding from Pfizer Inc. for a project not related to this research; ES received speaker fees from bfd buchholz fachinformationsdienst gmbh; PMT receives partial research support from Biogen, Inc., for research unrelated to this manuscript; MWW serves on Editorial Boards for Alzheimer & Dementia, and the Journal for Prevention of Alzheimer disease. He has served on Advisory Boards for Acumen Pharmaceutical, Alzheon, Inc., Cerecin, Merck Sharp & Dohme Corp., and NC Registry for Brain Health. He also serves on the USC ACTC grant which receives funding from Eisai for the AHEAD study. MWW has provided consulting to Boxer Capital, LLC, Cerecin, Inc., Clario, Dementia Society of Japan, Eisai, Guidepoint, Health and Wellness Partners, Indiana University, LCN Consulting, Merck Sharp & Dohme Corp., NC Registry for Brain Health, Prova Education, T3D Therapeutics, University of Southern California (USC), and WebMD. MWW has acted as a speaker/lecturer for China Association for Alzheimer Disease (CAAD) and Taipei Medical University, as well as a speaker/lecturer with academic travel funding provided by: AD/PD Congress, Cleveland Clinic, CTAD Congress, Foundation of Learning; Health Society (Japan), INSPIRE Project; U. Toulouse, Japan Society for Dementia Research, and Korean Dementia Society, Merck Sharp & Dohme Corp., National Center for Geriatrics and Gerontology (NCGG; Japan), University of Southern California (USC). MWW holds stock options with Alzeca, Alzheon, Inc., ALZPath, Inc., and Anven. MWW received support for his research from the following funding sources: National Institutes of Health (NIH)/NINDS/National Institute on Aging (NIA), Department of Defense (DOD), California Department of Public Health (CDPH), University of Michigan, Siemens, Biogen, Hillblom Foundation, Alzheimer Association, Johnson & Johnson, Kevin and Connie Shanahan, GE, VUmc, Australian Catholic University (HBI-BHR), The Stroke Foundation, and the Veterans Administration; AIC is currently employed by the Regeneron Genetics Center, a wholly-owned subsidiary of Regeneron Pharmaceuticals, Inc., and may hold Regeneron stock or stock options. All other authors declare no competing interestsFunding StatementThis project has received funding from the European Unions Horizon 2020 Research and Innovation Programme under the Specific Grant Agreement 945539 (Human Brain Project SGA3; QTAB: National Health and Medical Research Council (NHMRC), Australia (Project Grant ID: 1078756). QTIM: NHMRC (Project Grant IDs: 486682, 1009064); This project is supported by a grant overseen by the French National Research Agency (ANR) as part of the Investment for the Future Programme ANR18RHUS0002. It is also supported by an EU Joint Programme Neurodegenerative Disease Research (JPND) project through the following funding organisations under the aegis of JPND www.jpnd.eu: Australia, National Health and Medical Research Council, Austria, Federal Ministry of Science, Research and Economy; Canada, Canadian Institutes of Health Research; France, French National Research Agency; Germany, Federal Ministry of Education and Research; Netherlands, The Netherlands Organisation for Health Research and Development; United Kingdom, Medical Research Council. This project has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No 643417, No 640643, and No 667375 and 754517. The project also received funding from the French National Research Agency (ANR) through the VASCOGENE and SHIVA projects, and from the Initiative of Excellence of the University of Bordeaux (CSMART project). Computations were performed on the Bordeaux Bioinformatics Center (CBiB) computer resources, University of Bordeaux. Funding support for additional computer resources has been provided to SD by the Fondation Claude Pompidou. Three City Study (3CDijon): We thank the staff and the participants of the 3C Study for their important contributions. The 3C Study is conducted under a partnership agreement between the Institut National de la Sante et de la Recherche Medicale (INSERM), the Victor SegalenBordeaux II University, and SanofiAventis. The Fondation pour la Recherche Medicale funded the preparation and initiation of the study. The 3C Study is also supported by the Caisse Nationale Maladie des Travailleurs Salaries, Direction Generale de la Sante, Mutuelle Generale de lEducation Nationale (MGEN), Institut de la Longevite, Conseils Regionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of ResearchINSERM Programme Cohortes et collections de donnees biologiques. We thank A Boland (Centre National de Genotypage) for her technical help in preparing the DNA samples for analyses. This work was supported by the National Foundation for Alzheimers Disease and Related Disorders, the Institut Pasteur de Lille and the Centre National de Genotypage and the LABEX (Laboratory of Excellence program investment for the future) DISTALZ Development of Innovative Strategies for a Transdisciplinary approach to ALZheimers disease. Stephanie Debette and Christophe Tzourio are recipients of grants from the French National Research Agency (ANR), a grant from the Fondation Leducq, from Joint Programme for Neurodegenerative Disease Research (JPND, BRIDGET). Stephanie Debette is recipient of a grant from the European Research Council (ERC, SEGWAY). MarieGabrielle Duperron received a grant from the Fondation Bettencourt Schueller. This work was supported by the National Foundation for Alzheimers disease and related disorders, the Institut Pasteur de Lille, the labex DISTALZ and the Centre National de Genotypage. We thank Dr. Anne Boland (CNG) for her technical help in preparing the DNA samples for analyses. IMAGEN was funded by the European Unionfunded FP6 Integrated Project IMAGEN (LSHMCT2007037286). Further support was received from the following sources: the National Institutes of Health (NIH) (Consortium grant 5U54EB02040305ENIGMA) and National Institute on Aging (NIA) 1R56AG05885402ENIGMA World Aging Center); the Medical Research Council and Medical Research Foundation (ESTRA Neurobiological underpinning of eating disorders: integrative biopsychosocial longitudinal analyses in adolescents: grant MRR00465X; ESTRA Establishing causal relationships between biopsychosocial predictors and correlates of eating disorders and their mediation by neural pathways: grants MRS0203061), the Horizon 2020 funded ERC Advanced Grant STRATIFY (Brain network based stratification of reinforcementrelated disorders) (695313), the Medical Research Council (grant MRW0024181: Eating Disorders: Delineating illness and recovery trajectories to inform personalized prevention and early intervention in young people EDIFY), the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and Kings College London, the European Union (grant agreement no. 101057429environmentAL) and Innovate UK (grant agreement no. 10038599environmentAL) and the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC). The Austrian Stroke Prevention Study Family (ASPSFam) was funded by the Austrian Science Fund (FWF) grant number P20545P05, P13180, PI904 the Austrian National Bank Anniversary Fund, P15435, the Austrian Federal Ministry of Science, Research and Economy under the aegis of the EU Joint ProgrammeNeurodegenerative Disease Research (JPND)www.jpnd.eu and by the Austrian Science Fund P20545B05. The Medical University of Graz supports the databank of the ASPS. The authors thank the staff and the participants for their valuable contributions. We thank Birgit Reinhart for her longterm administrative commitment, Elfi Hofer for the technical assistance at creating the DNA bank, Ing Johann Semmler and Anita Harb for DNA sequencing and DNA analyses by TaqMan assays and Irmgard Poelzl for supervising the quality management processes after ISO9001 at the biobanking and DNA analyses. The research reported in this article The MCIC study was supported by the National Institutes of Health (NIHNCRR P41RR14075 and R01EB005846 (to Vince D Calhoun)), the Department of Energy (DEFG0299ER62764), the Mind Research Network, the Morphometry BIRN (1U24, RR021382A), the Function BIRN (U24RR02199201, NIHNCRR MO1 RR02575801, NIMH 1RC1MH089257 to Vince D Calhoun), the Deutsche Forschungsgemeinschaft (research fellowship to Stefan Ehrlich), and a NARSAD Young Investigator Award (to Stefan Ehrlich). The Atherosclerosis Risk in Communities study was performed as a collaborative study supported by National Heart, Lung, and Blood Institute (NHLBI) contracts (HHSN268201100005C, HSN268201100006C, HSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL70825, R01HL087641, R01HL59367, and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health (NIH) contract HHSN268200625226C. Infrastructure was partly supported by grant No UL1RR025005, a component of the NIH and NIH Roadmap for Medical Research. This project was partially supported by National Institutes of Health R01 grants HL084099 and NS087541 to MF. The authors thank the staff and participants of the ARIC study for their important contributions. NeuroIMAGE: This project was supported by grants from National Institutes of Health (grant R01MH62873 to SV Faraone) for initial sample recruitment, and from NWO Large Investment (grant 1750102007010 to JK Buitelaar), NWO Brain & Cognition (grant 43309242 to JK Buitelaar), and grants from Radboud University Medical Center, University Medical Center Groningen, Accare, and VU University Amsterdam for subsequent assessment waves. NeuroIMAGE also received funding from the European Communitys Seventh Framework Programme (FP7/2007 2013) under grant agreements n 602805 (Aggressotype), n 278948 (TACTICS), and n 602450 (IMAGEMEND), and from the European Communitys Horizon 2020 Programme (H2020/2014 2020) under grant agreements n 643051 (MiND), n 667302 (CoCA), and n 728018 (Eat2beNICE). BIG: This study used the BIG database, which was established in Nijmegen in 2007. This resource is now part of Cognomics, a joint initiative by researchers of the Donders Centre for Cognitive Neuroimaging, the Human Genetics and Cognitive Neuroscience departments of the Radboud university medical centre, and the Max Planck Institute for Psycholinguistics. The Cognomics Initiative is supported by the participating departments and centres and by external grants, including grants from the Biobanking and Biomolecular Resources Research Infrastructure (Netherlands) (BBMRINL) and the Hersenstichting Nederland. In particular, the authors would also like to acknowledge grants supporting their work from the Netherlands Organization for Scientific Research (NWO), i.e. the NWO Brain & Cognition Excellence Program (grant 43309229) and the Vici Innovation Program (grant 016 130669 to BF). Additional support is received from the European Communitys Seventh Framework Programme (FP7/2007 2013) under grant agreements n 602805 (Aggressotype), n 603016 (MATRICS), n 602450 (IMAGEMEND), and n 278948 (TACTICS), and from the European Communitys Horizon 2020 Programme (H2020/2014 2020) under grant agreements n 643051 (MiND) and n 667302 (CoCA). IMpACT: We acknowledge funding from the Netherlands Organization for Scientific Research (NWO), i.e. the Veni Innovation Program (grant 016196115 to MH) and the Vici Innovation Program (grant 016 130669 to BF). The work was also supported by grant U54 EB020403 to the ENIGMA Consortium from the BD2K Initiative, a crossNIH partnership, and by the European College of Neuropsychopharmacology (ECNP) Network ADHD Across the Lifespan. Munich Morphometry Sample (MPIP): The MPIP comprises images acquired as part of the Munich Antidepressant Response Signature Study and the Recurrent Unipolar Depression (RUD) CaseControl study performed at the MPIP, and control subjects acquired at the LudwigMaximiliansUniversity, Munich, Department of Psychiatry. We thank Eva Meisenzahl and Dan Rujescu for providing MRI and genetical data for inclusion into the MPIP Munich Morphometry sample. We wish to acknowledge Anna Olynyik and radiographers Rosa Schirmer, Elke Schreiter, Reinhold Borschke and Ines Eidner for image acquisition and data preparation. We thank Dorothee P. Auer for local study management in the initial phase of the RUD study. We are grateful to GlaxoSmithKline for providing the genotypes of the Recurrent Unipolar Depression CaseControl Satizabal et al. 131 Sample. We thank the staff of the Center of Applied Genotyping (CAGT) for generating the genotypes of the MARS cohort. The study is supported by a grant of the ExzellenzStiftung of the Max Planck Society. This work has also been funded by the Federal Ministry of Education and Research (BMBF) in the framework of the National Genome Research Network (NGFN), FKZ 01GS0481. SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs and the Social Ministry of the Federal State of MecklenburgWest Pomerania. Genomewide SNP typing in SHIP and MRI scans in SHIP and SHIPTREND have been supported by a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of MecklenburgWest Pomerania. The DCHS cohort is funded by the Bill & Melinda Gates Foundation [OPP 1017641]. The Age Gene/Environment SusceptibilityReykjavik Study has been funded by NIH contract N01AG12100 the NIA Intramural Research Program Hjartavernd the Icelandic Heart Association and the Althingi the Icelandic Parliament The study is approved by the Icelandic National Bioethics Committee VSN 00063 The researchers are indebted to the participants for their willingness to participate in the study The HUNT Study is a collaboration between HUNT Research Centre Faculty of Medicine and Movement Sciences NTNU Norwegian University of Science and Technology NordTrondelag County Council Central Norway Health Authority and the Norwegian Institute of Public Health HUNTMRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology and the Norwegian National Advisory Unit for functional MRI Role of the Funder/Sponsor The funding sources had no involvement in the study design data collection analysis and interpretation of data writing of the manuscript or the decision to submit the manuscript for publication Cardiovascular Health Study CHS This CHS research was supported by NHLBI contracts HHSN268201200036C HHSN268200800007C HHSN268201800001C N01HC55222 N01HC85079 N01HC85080 N01HC85081 N01HC85082 N01HC85083 N01HC85086 75N92021D00006 and NHLBI grants U01HL080295 R01HL087652 R01HL105756 R01HL103612 R01HL120393 and U01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke NINDS Additional support was provided through R01AG023629 from the National Institute on Aging NIA A full list of principal CHS investigators and institutions can be found at CHSNHLBIorg The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences CTSI grant UL1TR001881 and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center DRC grant DK063491 to the Southern California Diabetes Endocrinology Research Center Erasmus Rucphen family study ERF The ERF study as a part of EUROSPAN European Special Populations Research Network was supported by European Commission FP6 STRP grant number 018947 LSHGCT200601947 and also received funding from the European Communitys Seventh Framework Programme FP72007 2013grant agreement HEALTHF42007201413 by the European Commission under the programme Quality of Life and Management of the Living Resources of 5th Framework Programme no QLG2CT200201254 Highthroughput analysis of the ERF data was supported by a joint grant from the Netherlands Organization for Scientific Research and the Russian Foundation for Basic Research NWORFBR 047017043 Najaf Amin is supported by the Netherlands Brain Foundation project number F2013128 We are grateful to all study participants and their relatives general practitioners and neurologists for their contributions and to P Veraart for her help in genealogy J Vergeer for the supervision of the laboratory work and P Snijders for his help in data collection Framingham Heart Study FHS This work was supported by the National Heart Lung and Blood Institutes Framingham Heart Study Contract No N01HC25195 and No HHSN268201500001I and its contract with Affymetrix Inc for genotyping services Contract No N02HL64278 A portion of this research utilized the Linux Cluster for Genetic Analysis LinGAII funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center This study was also supported by grants from the National Institute of Aging R01s AG033040 AG033193 AG054076 AG049607 AG008122 AG016495 and U01AG049505 and the National Institute of Neurological Disorders and Stroke R01NS017950 We would like to thank the dedication of the Framingham Study participants as well as the Framingham Study team especially investigators and staff from the Neurology group for their contributions to data collection Dr DeCarli is supported by the Alzheimers Disease Center P30 AG 010129 The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart Lung and Blood Institute the National Institutes of Health or the US Department of Health and Human Services Genetic Study of Atherosclerosis Risk GeneSTAR is supported by grants from the National Institutes of Health National Institute of Neurological Disorders and Stroke R01NS062059 the National Institutes of Health National Heart Lung and Blood Institute U01 HL72518 HL087698 and the National Institutes of HealthNational Center for Research Resources M01RR000052 to the Johns Hopkins General Clinical Research Center We would like to thank the participants and families of GeneSTAR and our dedicated staff for all their sacrifices The Sydney Memory and Ageing Study Sydney MAS was funded by three National Health Medical Research Council NHMRC Program Grants ID No ID350833 ID568969 and APP1093083 DNA samples were extracted by Genetic Repositories Australia an Enabling Facility which was supported by an NHMRC Grant ID No 401184 MRI scans were processed with the support of NHMRC Project Grants 510175 and 1025243 and an ARC Discovery Project Grant DP0774213 and John Holden Family Foundation. The Older Australian Twins Study OATS was funded by a National Health & Medical Research Council NHMRC and Australian Research Council ARC Strategic Award Grant of the Ageing Well Ageing Productively Program ID No 401162 NHMRC Project seed Grants ID No 1024224 and 1025243 NHMRC Project Grants ID No 1045325 and 1085606 and NHMRC Program Grants ID No 568969 and 1093083 DNA was extracted by Genetic Repositories Australia which was funded by the NHMRC Enabling Grant 401184 This research study was facilitated through access to Twins Research Australia a national resource supported by a Centre of Research Excellence Grant ID No 1079102 from the National Health and Medical Research Council We would like to acknowledge the contributions of the Sydney MAS and OATS research teams and thank the study participants for their time and generosity in supporting this research The Lothian Birth Cohort LBC -1936 The work was undertaken as part of the Cross Council and University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology CCACE httpwwwccaceedacuk This work was supported by a Research into Ageing programme grant to IJD and the Age UKfunded Disconnected Mind project httpwwwdisconnectedmindedacuk to IJD and JMW with additional funding from the UK Medical Research Council MRC to IJD JMW and MEB The whole genome association part of this study was funded by the Biotechnology and Biological Sciences Research Council BBSRC Ref BBF0193941 JMW is supported by the Scottish Funding Council through the SINAPSE Collaboration httpwwwsinapseacuk the UK Dementia Research Institute the Row Fogo Charitable Trust and the Fondation Leducq CCACE MRC MRK0269921 is funded by the BBSRC and MRC The image acquisition and analysis was performed at the Brain Research Imaging Centre University of Edinburgh httpwwwbricedacuk partially funded by Row Fogo Charitable Trust Grant no BRODFID3668413 LIFEAdult LIFEAdult is funded by the Leipzig Research Center for Civilization Diseases LIFE LIFE is an organizational unit affiliated to the Medical Faculty of the University of Leipzig LIFE is funded by means of the European Union by the European Regional Development Fund ERDF and by funds of the Free State of Saxony within the framework of the excellence initiative project numbers 713241202 713241202 145052470 145752470 and by the German Research Foundation CRC1052 Obesity mechanisms Project A01 A VillringerM Stumvoll The authors would like to thank Matthias L Schroeter Leonie Lampe and Frauke Beyer for help with data acquisition and analysis and all participants and the staff at the LIFE study center NTR The NTR cohort was supported by the Netherlands Organization for Scientific Research NWO and The Netherlands Organisation for Health Research and Development ZonMW grants 90461090 98510002 91210020 90461193 48004004 46306001 45104034 40005717 Addiction31160008 016115035 48108011 05632010 Middelgroot91109032 OCWNWO Gravity programme024001003 NWOGroot 48015001674 Center for Medical Systems Biology CSMB NWO Genomics NBICBioAssistRK2008024 Biobanking and Biomolecular Resources Research Infrastructure BBMRI-NL 184021007 and 184033111 Spinozapremie NWO5646414192 KNAW Academy Professor Award PAH6635 and University Research Fellow grant URF to Dorret I Boomsma Amsterdam Public Health research institute former EMGO Neuroscience Amsterdam research institute former NCA the European Science Foundation ESF EUQLRT200101254 the European Communitys Seventh Framework Programme FP7 HEALTHF420072013 grant 01413 ENGAGE and grant 602768 ACTION the European Research Council ERC Starting 284167 ERC Consolidator 771057 ERC Advanced 230374 Rutgers University Cell and DNA Repository NIMH U24 MH06845706 the National Institutes of Health NIH R01D004215701A1 R01MH5879903 MH081802 DA018673 R01 DK09212704 Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995 the Avera Institute for Human Genetics Sioux Falls South Dakota USA Part of the genotyping and analyses were funded by the Genetic Association Information Network GAIN of the Foundation for the National Institutes of Health Computing was supported by NWO through grant 2018EW00408559 BiG Grid the Dutch eScience Grid and SURFSARA Religious Orders Study and Memory and Aging Project ROSMAP The clinical genomic and neuroimaging data for the Religious Orders Study and the Rush Memory and Aging Project was funded by NIH grants P30AG10161 RF1AG15819 R01AG17917 R01AG30146 R01AG40039 and the Translational Genomics Research Institute. Rotterdam Study (RSI, RSII, RSIII): The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), Research Institute for Diseases in the Elderly (RIDE), Ministry of Education, Culture and Science, Ministry for Health, Welfare and Sports, European Commission (DG XII), and Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists. The generation and management of GWAS genotype data for the Rotterdam Study (RS I, RS II, RS III) were executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera, Marjolein Peters, and Carolina Medina-Gomez for their help in creating the GWAS database, and Karol Estrada, Yurii Aulchenko, and Carolina Medina-Gomez for the creation and analysis of imputed data. This work has been performed as part of the CoSTREAM project (www.costream.eu) and has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No. 667375. SHIP is part of the Community Medicine Research Network of the University Medicine Greifswald, which is supported by the German Federal State of Mecklenburg-West Pomerania. LMGM is supported by a UQ Research Training Scholarship from The University of Queensland (UQ); IA is supported by Research Council of Norway (grant numbers 223273, 274359), KG Jebsen Foundation (grant number SKGJ-MED-008). Swedish Research Council (grant numbers K2012-61X-15078-09-3, K2015-62X-15077-12-3); OAA is supported by Research Council of Norway (#324499, 324252, 223273), NordForsk (#164218), KG Jebsen Stiftelsen (#SKGJ-MED-021), South East Norway Health Authority, NIH 1R01MH129742 - 01; KA is supported by R01AG064233, R01AG052200, UF1NS100599; AA is supported by European Union Horizon 2020 research and innovation programme, grant agreement 728018, project Eat2beNICE; LA is supported by Research Council of Norway (grant number: 223273 and 273446); MEB is supported by UK MRC; DAB is supported by P30AG10161, RF1AG15819, R01AG17917, R01AG30146, R01AG40039, and the Translational Genomics Research Institute; JCB is supported by Infrastructure for the CHARGE Consortium is supported in part by the National Heart, Lung, and Blood Institute grant R01HL105756; MPMB is supported by R01 MH090553; HB is supported by the NHMRC, Australia; JKB has been supported by the EUAIMS (European Autism Interventions) and AIMS-2-TRIALS programmes which receive support from Innovative Medicines Initiative Joint Undertaking Grant No. 115300 and 777394, the resources of which are composed of financial contributions from the European Unions FP7 and Horizon2020 Programmes, and from the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies in-kind contributions, and AUTISM SPEAKS, Autistica, and SFARI; and by the Horizon2020 supported programme CANDY Grant No. 847818. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Any views expressed are those of the author(s) and not necessarily those of the funders; VC is supported by NIH R01MH118695 and NSF 2112455; OTC is supported by NIH grants R01AG078533, U19AG078558, R01AG074258, R01AG077497, R01AG067765, R01AG041200, R01AG062309, R01AG062200, R01AG069476; CRKC is supported by R01 MH129742-01, R56 AG058854, R01 MH116147, U54 EB020403, Baszucki Brain Research Fund and the Milken Institutes Center for Strategic Philanthropy grant; AMD is supported by U24DA041123, U24DA041147; GDS works within the MRC Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council (MC_UU_00032/01); PLDJ is supported by U01 AG061356; CDeC is supported by R01 NS17050, R01AG054076, P30 AG072972; SEh and HW is supported by German Federal Ministry of Education and Research (BMBF) grants NGFNplus MooDS (Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia) and the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders) under the auspices of the e program (grant numbers O1ZX1314B and O1ZX1314G); SEF is supported by Max Planck Society; CF is supported by Max Planck Society (Germany); BFs contribution was supported by funding from the European Communitys Horizon 2020 Programme (H2020/2014 2020) under grant agreement n 847879 (PRIME). She also received relevant funding from the Netherlands Organization for Scientific Research (NWO) for the GUTS project (grant 024.005.011); KLG is supported by APP1173025; AH received support from the following sources: the Bundesministerium fur Bildung und Forschung (BMBF grants 01GS08152; 01EV0711; Forschungsnetz AERIAL 01EE1406A, 01EE1406B; Forschungsnetz IMAC-Mind 01GL1745B), the Deutsche Forschungsgemeinschaft (DFG grants SM 80/7-2, SFB 940, TRR 265, NE 1383/14-1); JJH is supported by 1P30AG066546-01A1, AG062531 and an endowment from the William Castella family as William Castella Distinguished University Chair for Alzheimers Disease Research; AJH is supported by NIH Grants U19 AG024904, P30 AG010133, P30 AG072976, R01 AG019771; LSc is supported by NHMRC Investigator Grant 2017962, NIH RO1 MH129832; HS is supported by Austrian National Bank Anniversary Fund, P15435, City Graz, Graz, Austria, and the Austrian Ministry of Science under the aegis of the EU Joint Programme Neurodegenerative Disease Research www.jpnd.eu; PRS is supported by National Health and Medical Research Council; GS is supported by European Union funded Horizon Europe project environMENTAL (101057429), the Horizon 2020 funded ERC Advanced Grant STRATIFY (695313), the National Natural Science Foundation of China (82202093); SS is supported by grants from the NIH: P30 AG066546, U01 AG052409, RF1 AG059421, R01 AG066524, UF1 AG054076, AG058589, NS125513, and NHLBI contract 75N92019D00031-0-75920220001; LSh is supported by NIH R01 AG058854, U01 AG068057, U01 AG066833, R01 AG071470; Work from the London Cohort was supported by research grants from the Wellcome Trust (grant 084730 to SMS.), University College London (UCL)/University College London Hospitals (UCLH) NIHR Biomedical Research Centre/Specialist Biomedical Research Centres (CBRC/SBRC); (grant 114 to SMS.), the European Union Marie Curie Reintegration (to M Matarin and SMS.), the UK NIHR (08-08-SCC), the Comprehensive Local Research Network (CLRN) Flexibility and Sustainability Funding (FSF) (grant CEL1300 to SMS.), The Big Lottery Fund, the Wolfson Trust, and the Epilepsy Society. This work was undertaken at UCLH/UCL, which received a proportion of funding from the UK Department of Healths NIHR Biomedical Research Centres funding scheme; JLS is supported by R01MH120125, R01MH118349, R56MH122819, R01MH121433; PMT and SIT are supported in part by NIH grants R01MH123163, R01MH121246, and R01MH116147. Core funding for ENIGMA was provided by the NIH Big Data to Knowledge (BD2K) program under consortium grant U54 EB020403 to PMT; DTT is supported by the Instituto de Salud Carlos III (00/3095, 01/3129, PI020499, PI14/00639, PI17/01056, and PI14/00918), SENY Fundaci Research Grant CI2005 0308007, and Fundacin Marqu s de Valdecilla. Instituto de investigacion sanitaria Valdecilla (A/02/07, NCT0235832 and NCT02534363); MCV is supported by Row Fogo Charitable Trust, grant no. Brod.FID3668413; DvdM is supported by the Research Council of Norway #324252 (PleioMent); JVB has been supported by funding from ISCIII (ref.: INT22/00029) and IDIVAL (ref.: INT/A21/10 and INT/A20/04); AV is supported by the State of Saxony; JMW is supported by the UK Dementia Research Institute (award no. UKDRI Edin002, DRIEdi1718, and MRC MC_PC_17113) which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimers Society, and Alzheimers Research UK; LBC1936 MRI brain imaging was supported by Medical Research Council (MRC) grants G0701120, G1001245, MR/M013111/1, and MR/R024065/1; Image analysis by the Row Fogo Charitable Trust; MWW is supported by U19AG024904; LTW is supported by The European Research Council under the European Unions Horizon 2020 research and Innovation program (ERC StG, Grant 802998); TW is supported by Intramural Research Program of the National Institutes of Health/; AW is supported by European Union, the European Regional Development Fund, the Free State of Saxony within the framework of the excellence initiative, the LIFE-Leipzig Research Center for Civilization Diseases, University of Leipzig [project numbers: 713-241202, 14505/2470, 14575/2470] and by grants of the German Research Foundation (DFG), contract grant numbers 209933838 CRC1052-03 A1 (AVW); JNT is supported by an NHMRC Leadership Fellowship GNT2009771, the Australian Government Department of Health and Aged Care, and the NSW Ministry of Health; JY is supported by P30AG10161, RF1AG15819, R01AG17917, R01AG30146, and the Translational Genomics Research Institute; SEM is supported by grants from the Australian NHMRC APP1158127 and APP1172917. MER thanks support from Australias National Health and Medical Research Council (GNT1102821) and the Rebecca L Cooper Medical Research Foundation (F20231230). Data used in the preparation from the Adolescent Brain Cognitive Development (ABCD) Study (https://abcdstudy.org), held in the NIMH Data Archive (NDA). This is a multisite, longitudinal study designed to recruit more than 10 000 children age 9-10 and follow them over 10 years into early adulthood. A full list of supporters is available at https://abcdstudy.org/federal-partners.html. A listing of participating sites and a complete listing of the study investigators can be found at https://abcdstudy.org/consortium_members/. ABCD consortium investigators designed and implemented the study and/or provided data but did not necessarily participate in the analysis or writing of this report. This manuscript reflects the views of the authors and may not reflect the opinions or views of the NIH or ABCD consortium investigators. The ABCD data repository grows and changes over time. The ABCD data used in this report came from DOI:10.15154/hmjn-g821. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our study is based on meta-analysis of previously published, publicly available data for which appropriate site-specific Institutional Review Boards and ethical review at local institutions have previously approved the use of these data. For full-details on the institutions that have approved the use of these data please refer to the Acknowledgments section.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDetailed information on how to access publicly available GWAS summary data from the ENIGMA and CHARGE consortia is reported on their corresponding publications2,12,15. Researchers can access individual-level data from the UKB and ABCD cohorts following the corresponding data application procedures. Work performed using UKB data was done under application 25331. Full genome-wide summary statistics generated in the present study are available at the ENIGMA website (https://enigma.ini.usc.edu/research/download-enigma-gwas-results). https://enigma.ini.usc.edu/research/download-enigma-gwas-results/